Key points are not available for this paper at this time.
Prevalence of residual excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) after treatment varies among studies. OSAREDS is a retrospective study involving 7 sleep Centres in Italy aimed at assessing prevalence of EDS and residual EDS after CPAP in OSA patients. An interim analysis showed that 861 patients (mean age±SD:56.5±8.8 yrs, BMI: 31.3±4.8 kg/m2, females: 25.8%) were seen at baseline and after 3-12 months (median 9.6 months) of CPAP treatment. Symptoms and compliance to CPAP were analyzed. Residual EDS was assessed as an Epworth Sleepiness Scale (ESS) score >10. Symptoms prevalence at diagnosis were: snoring 97.1%, fatigue 31.1%, insomnia 13.5%, and daytime sleepiness 36.5%; mean ESS score at diagnosis was 8.8±5.0. Mean symptoms duration was 61±41.6 months. Frequency of systemic hypertension, type 2 diabetes, asthma and COPD were 59.2, 16.0, 5.5, and 5.8%, respectively. CPAP was accepted by 98.7% of the patients, and 93.7% were on treatment at follow-up. Average therapeutic pressure was 8.3±3.7 cmH2O; mean CPAP use was 5.4±2.6 h/night for 77.7±25% of the nights. At follow-up, mean AHI was 6.1/h, mean ESS score was 4.6±3.7 (p<0.01 by t-test); prevalence of residual EDS in the whole sample fell to 6.6% (95% CI 5.0-8.3, p<0.01). Residual EDS was reported by 18% of OSA patients that had EDS at baseline. Prevalence rates of snoring, fatigue and insomnia at follow-up decreased to 12, 10.5, and 5.6%, respectively (p<0.0001 for all). Our preliminary results confirm that about one in 6 sleepy OSA patients at diagnosis remain sleepy after CPAP.
Bonsignore et al. (2022) studied this question.